Recommended Tests for Measuring Side Effects of Therapy
| Therapy | Side Effect | Recommended Tests | Guideline |
| Isotretinoin | Hyperlipidemia | Cholesterol, triglycerides* | Blom et al., 199131 |
| HMG-coenzyme inhibitors | Liver dysfunction | ALAT† | Van Binsbergen et al., 199149 |
| Muscular pain | CK‡ | Van Binsbergen et al., 199149 | |
| Ace-inhibitors, digoxine, diuretics | Not specified | K, Creatinine, Na§ | Walma et al., 199551 |
| Sulfasalazine | Anemia | Hb∥ | Schuurman et al., 199447 |
| Liver dysfunction | ALAT, gamma-GT∥ | Schuurman et al., 199447 | |
| Agranulocytosis | Thrombocytes, WBC, WBC-differentiation∥ | Schuurman et al., 199447 | |
| Not specified | Creatinine∥ | Schuurman et al., 199447 |
-
Note: HMG-coenzyme inhibitors indicates hydroxymethylglutaryl-CoA reductase inhibitors; ALAT, alanine aminotransferase; CK, creatine kinase; K, potassium; Na, sodium; Hb, hemoglobin; gamma-GT, gamma-glutamyltransferase; WBC, white blood cell (leukocyte) count.
-
↵* Baseline measurement of triglycerides at the start of treatment; subsequently, after four weeks, followed by evaluation every three months.
-
↵† Baseline measurement of ALAT at the start of treatment; subsequently, after four weeks.
-
↵‡ Creatine kinase measurement after four weeks of therapy (only when the patient complains of muscular pain).
-
↵§ Sodium measurement once every six months.
-
↵∥ Hemoglobin measurement every two weeks during the first three months of therapy; subsequently, every month.
